Development of a SPE LC-MS/MS Method Utilizing QuanRecovery Sample Plates with MaxPeak High Performance Surfaces for the Bioanalytical Quantification of Pramlintide from Serum

Significance of the topic

Pramlintide, a synthetic analogue of the hormone amylin, plays a key role as an adjunct therapy in diabetes management. Its low circulating levels in vivo and rapid pharmacokinetics demand highly sensitive bioanalytical methods. Accurate quantification of such peptides supports therapeutic monitoring and advances research into novel applications such as neurodegenerative disease models.

Study objectives and overview

This work aimed to develop a robust SPE LC-MS/MS assay for quantifying pramlintide in serum. Key goals included

• Efficient cleanup of complex biological matrices
• Mitigation of peptide adsorption losses
• Optimization of chromatographic separation and MS detection
• Achieving low pg/mL limits of quantification in rat and human serum

Methodology and instrumentation

A mixed-mode SPE protocol using Oasis WCX μElution plates was optimized to extract pramlintide from 100 μL serum samples. Recovery was increased by adjusting loading and wash steps to pH conditions favoring peptide retention. QuanRecovery plates with MaxPeak high performance surfaces prevented non-specific binding during sample storage.
Chromatographic separation employed an ACQUITY UPLC Peptide CSH C18 column operated at 60 °C with a tailored gradient from 22 to 27 percent acetonitrile over 3 minutes to minimize matrix suppression. MS detection was performed on a Xevo TQ-XS tandem quadrupole with ESI in positive mode, monitoring the 988.36 > 968.11 m/z transition for quantification and a confirmatory 988.36 > 930.78 m/z transition.

Main results and discussion

Initial SPE and storage plates yielded improved pramlintide recoveries. QuanRecovery plates achieved nearly 100 percent recovery versus under 3 percent on polypropylene. Optimized SPE conditions increased recovery to about 75 percent. The refined chromatographic method reduced matrix suppression from roughly 20 percent to below 10 percent and improved signal to noise. The assay showed linear response from 25 to 50 000 pg/mL with r2 above 0.995 and a lower limit of quantification of 25 pg/mL. Precision was below 5 percent CV and accuracy within 10 percent in both rat and human serum.

Benefits and practical applications

• Rapid sample preparation under 2 hours for high throughput analysis
• Minimized peptide loss without carrier proteins
• Robust quantification at low pg/mL levels
• Applicable to pharmacokinetic and biomarker studies

Future trends and applications

Emerging developments include even more inert sample containers, integration of microflow LC for enhanced sensitivity, and exploration of high resolution mass spectrometry to further reduce matrix effects. These advances will broaden peptide bioanalysis in drug development and biomarker discovery.

Conclusion

This SPE LC-MS/MS method combines tailored mixed-mode extraction, high performance sample plates, and optimized UPLC-MS conditions to achieve sensitive and accurate quantification of pramlintide in serum. The approach supports advanced peptide bioanalysis in both preclinical and clinical contexts.

References

1. Center for Drug Evaluation and Research Clinical Pharmacology and Biopharmaceutics Review for pramlintide acetate FDA document 21–332
2. SYMLIN product information and patent status report
3. Mohamed LA Zhu H Mousa YM et al J Alzheimers Dis 2017 56(3)1087–1099
4. Rabe M Verdes D Seeger S Understanding protein adsorption at solid surfaces Adv Colloid Interface Sci 2011 162(1-2)87–106